← All sectors / The AI transformation
163 · Wearables & continuous biometric monitoring
The body reporting continuously
Curve position
Binding constraint
Clinical validation that turns a consumer signal into a medical one.
Why this sector sits at Orbit
Wearables and continuous biometric monitoring is a large, established consumer and clinical market ($86.8B in 2025) growing at an ordinary ~12% CAGR, dominated by Apple, Fitbit/Google, Garmin, and Oura competing on accuracy, ecosystem integration, and premium pricing rather than on technology access.
Reviewed on a two month cycle. The position moves only when a dated, verifiable change in the binding constraint justifies it.
Heatmap / How this sector's stocks are moving
| Stock | Price | 1 Day | 1 Week | 1 Month | Year to date |
|---|---|---|---|---|---|
| $GRMN | $289.15 | +6.52% | +6.11% | +3.56% | +42.54% |
| $DXCM | $88.48 | +6.64% | +12.54% | +6.10% | +33.31% |
| $AAPL | $349.51 | +5.31% | +1.65% | +4.76% | +28.56% |
| $IRTC | $134.00 | +6.04% | +8.07% | +25.00% | −24.48% |
| Sector average | +6.13% | +7.09% | +9.86% | +19.98% |
Prices as of November 5, 2026. The sector's move is the equal-weighted average of these listed companies, a market proxy for context, not recommendations. See it on the full heatmap →
Sentiment / The mood in this sector's stocks
Since 2018, Wearables & continuous biometric monitoring has been in Optimism and steady 20 separate times. After those, its stocks beat their usual three months 9 times (45%), by a median of −3.1 points.
Confidence: low, a split like this is common by chance, so no edge is called.
Consumer devices now collect biological data continuously that used to require a clinic visit to obtain once. The interesting shift is not the sensing, which largely works, but the transition from consumer curiosity to data a clinician will actually act on.
Historically wearables measured steps and sleep with debatable accuracy, and clinicians ignored the output because it was unvalidated and unreliable. Cleared sensors changed that for specific measurements.
The structural driver is chronic disease management. Conditions requiring continuous adjustment, particularly metabolic ones, benefit enormously from continuous rather than episodic measurement.
The technology layer spans continuous glucose sensing, cardiac rhythm detection with regulatory clearance, sleep staging, blood pressure without a cuff which remains unsolved, and the analytics that turn a stream into an alert worth acting on.
Adoption economics work when a payer covers the device or when the data prevents an expensive event. Consumer purchase alone supports a much smaller market than the clinical channel.
The beneficiaries include continuous sensor makers, device companies with cleared measurements, analytics firms turning signals into clinical alerts, and the pharmaceutical companies using the data in trials.
The value chain runs from sensor through device and analytics to clinician or consumer. Sensor accuracy with regulatory clearance is the moat; the wristband around it is not.
The overlooked layer includes sensor component suppliers, clinical validation firms, data integration vendors connecting devices to records, and the specialty pharmacies distributing prescribed sensors.
Competitive dynamics favour companies with clearance and payer coverage, since consumer brands without either compete on features that commoditise quickly.
Risks: consumer hardware is brutally competitive, clinical validation is slow and expensive, coverage decisions gate the larger market, and adherence drops sharply after the first months.
What to watch: sensor coverage decisions by payers, clearance approvals for new measurements, prescription volumes for continuous sensors, and adherence data beyond ninety days.